Published in J Med Chem on September 07, 2006
Current research on opioid receptor function. Curr Drug Targets (2012) 1.07
Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. ACS Chem Neurosci (2010) 0.96
Endogenous opiates and behavior: 2006. Peptides (2007) 0.92
Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org Lett (2009) 0.90
Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem (2007) 0.83
Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem (2008) 0.82
Further studies on the effect of lysine at the C-terminus of the Dmt-Tic opioid pharmacophore. Bioorg Med Chem (2007) 0.82
Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem (2010) 0.80
Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph. Pharmacol Biochem Behav (2008) 0.79
Synthesis of a potent and selective (18)F-labeled delta-opioid receptor antagonist derived from the Dmt-Tic pharmacophore for positron emission tomography imaging. J Med Chem (2008) 0.79
Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice. Eur J Pharmacol (2009) 0.78
A DFT and semiempirical model-based study of opioid receptor affinity and selectivity in a group of molecules with a morphine structural core. Int J Med Chem (2012) 0.75
Engineering endomorphin drugs: state of the art. Expert Opin Ther Pat (2012) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Some quantitative uses of drug antagonists. Br J Pharmacol Chemother (1959) 41.90
Naltrexone in the treatment of alcohol dependence. N Engl J Med (2001) 4.68
A potent and selective endogenous agonist for the mu-opiate receptor. Nature (1997) 3.87
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology (2003) 3.66
The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem (1999) 1.84
Opioids and alcoholism. Physiol Behav (2004) 1.67
mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther (2000) 1.67
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A (2005) 1.44
Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci (2004) 1.42
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem (2002) 1.40
Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists. Proc Natl Acad Sci U S A (1992) 1.40
Dmt and opioid peptides: a potent alliance. Biopolymers (2003) 1.40
Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med (1995) 1.34
Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl) (2001) 1.26
Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem (2002) 1.23
Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo. J Pharmacol Exp Ther (1989) 1.13
Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism. J Med Chem (1999) 1.11
Neuroprotective role of delta-opioid receptors in cortical neurons. Am J Physiol Cell Physiol (2002) 1.09
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem (2004) 1.08
Dermorphin gene sequence peptide with high affinity and selectivity for delta-opioid receptors. J Biol Chem (1989) 1.07
Delta opioid peptide (D-Ala 2, D-Leu 5) enkephalin: linking hibernation and neuroprotection. Front Biosci (2004) 1.06
Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. J Med Chem (1997) 1.05
6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem (2006) 1.02
Function of negative charge in the "address domain" of deltorphins. J Med Chem (1991) 1.02
Endomorphin 2 analogues containing Dmp residue as an aromatic amino acid surrogate with high mu-opioid receptor affinity and selectivity. Bioorg Med Chem (2003) 0.97
Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res (2005) 0.97
Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism. J Med Chem (2004) 0.96
Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem (2004) 0.96
Interaction of deltorphin with opioid receptors: molecular determinants for affinity and selectivity. Peptides (1993) 0.95
Selective opioid dipeptides. Biochem Biophys Res Commun (1994) 0.94
Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). J Med Chem (2005) 0.91
Agonist-specific regulation of the delta-opioid receptor. Life Sci (2004) 0.89
Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism. Bioorg Med Chem (2003) 0.89
Exogenous activation of delta- and kappa-opioid receptors affords cardioprotection in isolated murine heart. Basic Res Cardiol (2003) 0.88
A new structural motif for mu-opioid antagonists. J Med Chem (2005) 0.87
NPY-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. Peptides (2005) 0.86
Opioid peptide-derived analgesics. AAPS J (2005) 0.86
Synthesis and biological activity of the first cyclic biphalin analogues. Bioorg Med Chem Lett (2005) 0.85
From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem (2005) 0.82
DADLE induces a reversible hibernation-like state in HeLa cells. Histochem Cell Biol (2005) 0.81
Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. Peptides (2000) 0.80
Design of mu selective opioid dipeptide antagonists. FEBS Lett (1997) 0.80
New scaffolds in the development of mu opioid-receptor ligands. Bioorg Med Chem Lett (2003) 0.79
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem (2002) 1.99
The tachykinin peptide family. Pharmacol Rev (2002) 1.82
Dmt and opioid peptides: a potent alliance. Biopolymers (2003) 1.40
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem (2002) 1.40
Copper-catalyzed enantioselective substitution of allylic carbonates with diboron: an efficient route to optically active alpha-chiral allylboronates. J Am Chem Soc (2007) 1.36
Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogues. Bioorg Med Chem Lett (2007) 1.30
New potential anticancer agents based on the anthranilic acid scaffold: synthesis and evaluation of biological activity. J Med Chem (2005) 1.25
The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci U S A (2009) 1.24
Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem (2002) 1.23
Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry (2009) 1.17
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol (2002) 1.14
Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem (2006) 1.13
Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol (2007) 1.11
Interaction of sweet proteins with their receptor. A conformational study of peptides corresponding to loops of brazzein, monellin and thaumatin. Eur J Biochem (2004) 1.11
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev (2010) 1.09
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J Pharmacol Exp Ther (2007) 1.09
Synthesis and antiproliferative activity of 2,6-dibenzylamino-3,5-dicyanopyridines on human cancer cell lines. Eur J Med Chem (2005) 1.08
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem (2009) 1.08
Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. J Neurochem (2012) 1.07
Current research on opioid receptor function. Curr Drug Targets (2012) 1.07
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci (2005) 1.06
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides (2007) 1.05
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther (2008) 1.05
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol (2004) 1.04
Synthesis and in vitro antitumor activity of new 4,5-dihydropyrazole derivatives. Bioorg Med Chem (2010) 1.04
Solution structure of amyloid beta-peptide (25-35) in different media. J Med Chem (2004) 1.04
6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem (2006) 1.02
Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2. J Med Chem (2005) 1.02
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev (2005) 1.01
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem (2006) 1.00
Triazine compounds as antagonists at Bv8-prokineticin receptors. J Med Chem (2008) 0.99
Neuroendocrine profile in a rat model of psychosocial stress: relation to oxidative stress. Antioxid Redox Signal (2013) 0.98
Endomorphin 2 analogues containing Dmp residue as an aromatic amino acid surrogate with high mu-opioid receptor affinity and selectivity. Bioorg Med Chem (2003) 0.97
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides (2010) 0.97
Activation of DOR attenuates anoxic K+ derangement via inhibition of Na+ entry in mouse cortex. Cereb Cortex (2008) 0.96
Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism. J Med Chem (2004) 0.96
Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. ACS Chem Neurosci (2010) 0.96
Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem (2004) 0.96
Novel 2',6'-dimethyl-L-tyrosine-containing pyrazinone opioid mimetic mu-agonists with potent antinociceptive activity in mice. J Pharmacol Exp Ther (2004) 0.96
Synthesis and biological activity of human neuropeptide S analogues modified in position 2. J Med Chem (2008) 0.95
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J Pharmacol Exp Ther (2007) 0.95
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci (2004) 0.95
Interaction of calmodulin with the phosphofructokinase target sequence. FEBS Lett (2004) 0.95
A new ligand for the urotensin II receptor. Br J Pharmacol (2002) 0.95
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.95
delta-Opioid receptors protect from anoxic disruption of Na+ homeostasis via Na+ channel regulation. Cell Mol Life Sci (2009) 0.94
Structural studies of [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond. Bioorg Med Chem (2003) 0.94
Conformation-activity relationship of neuropeptide S and some structural mutants: helicity affects their interaction with the receptor. J Med Chem (2007) 0.94
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides (2007) 0.93
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists. J Med Chem (2009) 0.92
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol (2009) 0.92